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ABSTRACT 
Background  
 Myelin basic protein (MBP), a crucial neuro-autoantigen involved in the maintenance of the 
myelin sheath, is one of the biomarkers of therapeutic response in multiple sclerosis (MS). This 
neuroinflammatory autoimmune disease might result from molecular mimicry of MBP. The 
present study examines its role as a prognostic biomarker and evaluates the molecular mimicry 
hypothesis of MS etiology by using MBP to induce the immune system. MBP was used at varying 
concentrations to assess the optimum concentration of the antigen required to induce cellular 
immunity and to understand its prognostic value to facilitate early diagnosis in MS.  
Method  
A novel methodology combining molecular techniques was used to confirm the antigenic 
properties of MBP and study its efficiency in increasing the susceptibility to MS. Three groups of 
thirty subjects each, untreated MS, untreated MS with and without family history, and untreated 
MS at two different time points from diagnosis (early: 1-15 and late: 15-23 days) were recruited 
for the study. Healthy individuals were recruited to serve as controls. Peripheral blood 
mononuclear cells (PBMCs) and plasma was used for the retrieval of MBP and IgG assay, 
respectively.  
We used a novel in silico procedure to select antigenic MBP sequences based on T-cell and B-cell 
predictions, conserved selected epitopes, multiple alignment, and BLASTP ClustalW for 
presenting the motifs common to all six human MBP isoforms. Then, experiments were conducted 
by the slope line derived from the measured IgG serum levels in untreated MS patients and healthy 
individuals against the MBP epitope of untreated MS patients and healthy individuals. 
Results  
The optimum concentration of the MBP epitope for the immune system to react and facilitate 
prognostication was found to be 50 and 150 µg/mL in MS patients and healthy individuals, 
respectively. Combined results from ELISA and real-time PCR showed that the total IgG and the 
ratio of gene expression for candidate human MBP epitope was higher in MS patients in all the 
three groups compared to that in healthy controls.  
By performing a bioinformatics analysis starting with common epitopic fragments for classic and 
non-classic MBP isoforms, we predicted four epitopic regions of human MBP sequences based on 
antigenic priority: 110–124, 7–21, 38–52, and 156–170. The collections of viral and bacterial 
protein families with 100% pattern- similarity exhibited cross-reactivity between MBP epitopes 
and 15 proteins in 16 bacteria and 39 proteins in 43 viruses. IgG assay revealed that the 
concentration of IgG in healthy controls was less than that in patients.  
Conclusions  
Molecular assays in the early stages of the disease could help in elucidating the effectiveness of 
the MBP as a prognostic factor in MS. Future research in the field of biomarker detection for MS 
would benefit from a targeted approach that would enhance accuracy, be economical, and provide 
leads for the development of the personalized treatment for MS. 
The predicted candidate MBP epitope confirmed stimulation of the immune system by increasing 
total IgG in patient sera. The results suggest that bioinformatics can guide in vitro work. Future 
research on autoantigenic targets of the central nervous system in combination with precise 
experimental observations might explain MS etiology and facilitate individualized treatments. 
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